A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (STELLAR-002)
Associated ConditionsMultiple Tumor Types
You are being asked to take part in a clinical research study called STELLAR-002 because you have been diagnosed with cancer or your cancer has worsened since your last treatment. If you join this study, you will receive an investigational drug called XL092 as a single agent or in combination with nivolumab, nivolumab plus ipilimumab, or nivolumab/relatlimab fixed dose combination. Nivolumab and Ipilimumab, also known as Opdivo and Yervoy respectively, are approved medicines for a number of different types of cancer. Nivolumab and relatlimab fixed dose combination, also known as Opdualag, is an FDA approved drug for use in people with melanoma cancer and is currently being studied for treatment in other types of cancers. An investigational drug is a drug that has not been approved by the United States’ Food and Drug Administration (FDA), European Medicines Agency (EMA) or by a similar government health authority in another country or region.
This study is currently enrolling.